ArticleDermatology and therapy2026
Dupilumab Treatment Provides Multidimensional Benefits in Patients with Prurigo Nodularis.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable
A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn pooled LIBERTY-PN PRIME/PRIME2 trials on prurigo nodularis (PN), at week 24, the stringent composite endpoint of a ≥ 4-point reduction from baseline in Worst Itch Numeric Rating Scale (WI-NRS) score combined with an Investigator's Global Assessment for PN-Stage (IGA PN-S) score of 0/1 (clear/almost clear skin) was achieved by 35.3% of dupilumab versus 8.9% of placebo-treated patients. This optimal response may not capture the full experience of treatment in the remaining patients. This study assessed additional efficacy endpoints in the remaining dupilumab (64.7%) and placebo (91.1%) PRIME/PRIME2 recipients without optimal response at week 24.
methodsAdditional week 24 endpoints included ≥ 9-point reduction from baseline in Dermatology Life Quality Index (DLQI) score, Patient Global Impression of Severity (PGIS) score of "none"/"mild," ≥ 75% healed lesions from Prurigo Activity and Severity (PAS-75), and a concomitant reduction from baseline of ≥ 3 points in WI-NRS score and ≥ 1 point in IGA PN-S score.
resultsData from 99 dupilumab-treated and 144 placebo-treated patients without optimal response were analyzed. Among dupilumab-treated patients, 61.1% achieved a ≥ 9-point reduction from baseline in DLQI score, 55.8% a PGIS score of "none" or "mild," 53.7% PAS-75, and 45.7% the less stringent itch and skin lesion composite endpoint (nominal P vs placebo significant for all).
conclusionDupilumab treatment versus placebo resulted in nominally significant improvements in signs, symptoms, and quality of life in patients with PN without optimal response by week 24, supporting the benefits of continued treatment. These results highlight the need to develop a treat-to-target strategy for the long-term management of PN.
trial registrationClinicalTrial.gov Identifiers: NCT04183335 and NCT04202679 (registered December 2019).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.